Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • In a news article by the Wall Street Journal, Pfizer Inc (NYSE:PFE) is reportedly in early-stage talks to acquire Seagen Inc (NASDAQ:SGEN) for over $30 billion.
  • In June last year, the Wall Street Journal reported that Merck & Co Inc (NYSE:MRK) showed interest in buying Seagen
  • In the article, the deal was reported to be a price of at least $200 a share, equivalent to roughly $40 billion or more.
  • William Blair writes that since the discussions between Seagen and Pfizer are reported to be "early stage" in nature, it cautions investors not to overreact to the news. 
  • Keeping its top pick, the analyst reiterates its Outperform rating on Seagen.
  • If the deal happens, with the M&A process, there will be several hurdles to overcome (including FTC concerns), and the entire process could take months to materialize. 
  • The analyst says it would be surprised by a decision to sell the company unless it transacts at or above the previously reported price of $40 billion (or $215 per share)
  • William Blair's bullish thesis is based on the long-term growth potential, driven by approved products—Adcetris, Padcev, Tukysa, and Tivdak; and expanding late- and early-phase assets within the company's pipeline. 
  • Although, the analyst said some volatility is expected due to the potential of Padcev to disrupt the urothelial carcinoma space with the upcoming approval on or before April 21.
  • Price Action: SGEN shares are up 9.62% at $176.90 on the last check Monday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorBiotechLarge CapM&ANewsHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas